LV-Visio-AMTRIX
Phase 2Biologic
LV-Visio-AMTRIX is one of 23 biologic programs targeting Keratitis. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
55 competitors in Keratitis
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Neoral
NovartisApproved
Levaquin
WWim Janssens
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acthar
MMallinckrodt
Approved
OXERVATE
DDompé Farmaceutici S.p.A
Approved
Cenegermin
DDompé Farmaceutici S.p.A
Approved
Oxervate
DDompé Farmaceutici S.p.A
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LV-Visio-AMTRIX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- TTBF Genie Tissulaire